RESEARCH TRIANGLE PARK, N.C. -- Talecris Biotherapeutics, Inc. announced today the U.S. Food and Drug Administration (FDA) has granted a Priority Review of Gamunex (Immune Globulin Intravenous [Human] ...
RESEARCH TRIANGLE PARK, N.C. (April 23, 2009) — Talecris Biotherapeutics, Inc. today announced the publication of the health-related quality of life results from the largest clinical trial ever ...
Gamunex-C (immune globulin [human]) infusion can cause side effects, such as headache, nausea, fatigue, and infusion reactions. Some serious side effects include aseptic meningitis and risks of blood ...
RESEARCH TRIANGLE PARK, N.C., Oct. 14 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics (Nasdaq: TLCR) announced today that the U.S. Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results